Format

Send to

Choose Destination
See comment in PubMed Commons below

The topical calcineurin inhibitor pimecrolimus in atopic dermatitis: a safety update.

Author information

1
Zentrum der Dermatologie und Venerologie, Johann Wolfgang Goethe-Universität, Theodor-Stern-Kai 7, D 60590 Frankfurt/ Main, Germany. thaci@em.uni-frankfurt.de

Abstract

Atopic eczema is a chronic inflammatory skin disorder with a relapsing and remitting course. For many decades,topical corticosteroids have been the mainstay therapy for atopic dermatitis. After the introduction of calcineurin inhibitors as a corticosteroid-free alternative, there were high expectations. After the black box warning from the FDA regarding the potential theoretical risk for developing neoplasia under treatment with calcineurin inhibitors, patients and physicians became uncertain about its safety, regardless of the fact that current scientific data do not support increased concern for risk of malignancy.

PMID:
17992459
[Indexed for MEDLINE]
Free full text
PubMed Commons home

PubMed Commons

0 comments
How to join PubMed Commons

    Supplemental Content

    Full text links

    Icon for Slovenian Dermatovenerological Society
    Loading ...
    Support Center